{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intravenous+fluid+treatment&page=2",
    "query": {
      "intervention": "intravenous fluid treatment",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 269,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intravenous+fluid+treatment&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intravenous+fluid+treatment&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T13:55:03.892Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05984602",
      "title": "A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 9,
      "start_date": "2023-07-14",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 3,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05984602"
    },
    {
      "nct_id": "NCT02792699",
      "title": "Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "ABP 798",
          "type": "DRUG"
        },
        {
          "name": "Rituximab (US)",
          "type": "DRUG"
        },
        {
          "name": "Rituximab (EU)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 311,
      "start_date": "2016-05-17",
      "completion_date": "2018-10-08",
      "has_results": true,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 27,
      "location_summary": "Tuscaloosa, Alabama • Los Angeles, California • Thousand Oaks, California + 24 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02792699"
    },
    {
      "nct_id": "NCT02287064",
      "title": "An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinocerebellar Ataxias"
      ],
      "interventions": [
        {
          "name": "Intravenous Immune Globulin (IVIG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 10,
      "start_date": "2015-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-06-08",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287064"
    },
    {
      "nct_id": "NCT06980480",
      "title": "A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Secondary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "IGI, 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 183,
      "start_date": "2026-01-14",
      "completion_date": "2028-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 7,
      "location_summary": "Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06980480"
    },
    {
      "nct_id": "NCT01175213",
      "title": "Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases (PID)"
      ],
      "interventions": [
        {
          "name": "SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IV treatment with IGSC, 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2010-07-28",
      "completion_date": "2013-08-06",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 11,
      "location_summary": "Cypress, California • Irvine, California • Los Angeles, California + 8 more",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01175213"
    },
    {
      "nct_id": "NCT06921603",
      "title": "POCUS-Guided Diuresis for Decompensated Heart Failure",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Decompensation, Acute",
        "Acute Kidney Injuries"
      ],
      "interventions": [
        {
          "name": "Furosemide (Standard Diuretic) Treatment",
          "type": "OTHER"
        },
        {
          "name": "POCUS-Assessed Diuretic Management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 588,
      "start_date": "2025-06-29",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 5,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06921603"
    },
    {
      "nct_id": "NCT03401073",
      "title": "IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Fiber Neuropathy",
        "Idiopathic Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2018-09-01",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401073"
    },
    {
      "nct_id": "NCT03554317",
      "title": "COMbination of Bipolar Androgen Therapy and Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-resistant Prostate Cancer",
        "Metastatic Prostate Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2018-09-05",
      "completion_date": "2023-01-06",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03554317"
    },
    {
      "nct_id": "NCT01365793",
      "title": "Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebral Edema",
        "Diabetic Ketoacidosis"
      ],
      "interventions": [
        {
          "name": "0.45% saline replacement fluid",
          "type": "DRUG"
        },
        {
          "name": "0.9% saline replacement fluid",
          "type": "DRUG"
        },
        {
          "name": "0.45% saline intravenous fluid",
          "type": "DRUG"
        },
        {
          "name": "0.9% saline Intravenous fluid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 1389,
      "start_date": "2010-11",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2018-06-25",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 13,
      "location_summary": "Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 10 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365793"
    },
    {
      "nct_id": "NCT01128413",
      "title": "Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Shock"
      ],
      "interventions": [
        {
          "name": "Cheetah NICOM® PLRT",
          "type": "DEVICE"
        },
        {
          "name": "USCOM ® (Ultrasound Cardiac Output Monitor)",
          "type": "DEVICE"
        },
        {
          "name": "Inferior Vena Cava (IVC) Ultrasound Collapsibility",
          "type": "DEVICE"
        },
        {
          "name": "CURVES Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Lactate Clearance",
          "type": "BIOLOGICAL"
        },
        {
          "name": "500ml Normal Saline Bolus",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clinician Discretion Intravenous Fluid Management",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL",
        "BIOLOGICAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2010-07",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2016-04-01",
      "last_synced_at": "2026-10-07T13:55:03.892Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01128413"
    }
  ]
}